Ambrisentan: A guide to its use in pulmonary arterial hypertension classified as WHO functional class II or III

[31] McGoon M., Ambrisentan therapy in patients with pulmonary arterial hypertension receiving concomitant sildenafil therapy: An analysis of the ARIES-3 study [abstract], Am J Respir Crit Care Med, 181, (2010)

[32] McGoon M.D., Frost A.E., Oudiz R.J., Et al., Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bo-sentan or sitaxsentan due to liver function test abnormalities, Chest, 135, 1, pp. 122-9, (2009)

[33] Feldman J.P., Keogh A., ARIES-3: Long-term ambrisentan therapy in patients with pulmonary hypertension who previously discontinued bosentan or sitaxsentan due to liver function abnormalities [abstract], 74th Annual Meeting of the American College of Chest Physicians, (2008)

[31] McGoon M., Ambrisentan therapy in patients with pulmonary arterial hypertension receiving concomitant sildenafil therapy: An analysis of the ARIES-3 study [abstract], Am J Respir Crit Care Med, 181, (2010)

[32] McGoon M.D., Frost A.E., Oudiz R.J., Et al., Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bo-sentan or sitaxsentan due to liver function test abnormalities, Chest, 135, 1, pp. 122-9, (2009)

[33] Feldman J.P., Keogh A., ARIES-3: Long-term ambrisentan therapy in patients with pulmonary hypertension who previously discontinued bosentan or sitaxsentan due to liver function abnormalities [abstract], 74th Annual Meeting of the American College of Chest Physicians, (2008)